Abstract:FKBP51 is well-known as a cochaperone of Hsp90 machinery and implicated in many human diseases including stress-related diseases, tau-mediated neurodegeneration and cancers, which makes FKBP51 an attractive drug target for the therapy of FKBP51-associated diseases. However, it has been reported that only nature product rapamycin, cyclosporine A, FK506 and its derivatives exhibit good binding affinities when bound to FKBP51 by now. Given the advantages of peptide-inhibitors, we designed and obtained 20 peptide-inhibitor hits through structure-based drug design. We further characterized the interaction modes of the peptide-inhibitor hits on the FK1 domain of FKBP51 by biochemical and structural biology methods. Structural analysis revealed that peptide-inhibitor hits form U-shaped conformations and occupy the FK506 binding pocket and share similar interaction modes with FK506. Using molecular dynamics simulations, we delved into the interaction dynamics and found that hits are anchored to the FK506 binding pocket in a quite stable conformation. Meanwhile, it was shown that interactions between FK1 and peptide-inhibitor hits are mainly attributed to the hydrogen bond networks comprising I87 and Y113 and FPF cores of peptide-inhibitors involved extensive hydrophobic interactions. We presumed that the peptide design strategy based on the small molecule structure probably shed new lights on the peptide-inhibitor discovery of other targets. The findings presented here could also serve as a structural basis and starting point facilitating the optimization and generation of FKBP51 peptide-inhibitors with better bio-activities.Peptide-inhibitor hits were designed with small molecules published before used as the starting point through structure-based drug design and biochemically andstructurally characterized the interaction modes between the FK1 domain of FKBP51 and hitsDownload : Download high-res image (86KB)Download : Download full-size image

1,4‐Pyrazolyl‐containing SAFit‐analogues are selective FKBP51 inhibitors with improved ligand efficiency and drug‐like profile

Potential inhibitors for FKBP51: an in silico study using virtual screening, molecular docking and molecular dynamics simulation

Molecular Dynamics Simulation, Binding Free Energy Calculation and Unbinding Pathway Analysis on Selectivity Difference Between FKBP51 and FKBP52: Insight into the Molecular Mechanism of Isoform Selectivity

Discovery of pentapeptide-inhibitor hits targeting FKBP51 by combining computational modeling and X-ray crystallography

Binding Modes and Conformational Changes of FK506-binding Protein 51 Induced by Inhibitor Bindings: Insight into Molecular Mechanisms Based on Multiple Simulation Technologies

Structure-based discovery of small molecule inhibitors of FKBP51-Hsp90 protein-protein interaction

Structure‐Based Design of Ultrapotent Tricyclic Ligands for FK506‐Binding proteins

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2)

Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors.

Synthesis, Biological Evaluation and Molecular Docking Studies of Novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone Derivatives

FK506-binding protein ligands: structure-based design, synthesis, and neurotrophic/neuroprotective properties of substituted 5,5-dimethyl-2-(4-thiazolidine)carboxylates.

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Sulfonamide Moiety As Novel FAK Inhibitors

Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domain

Discovery of novel pyrrolo [2,3-d] pyrimidine derivatives as potent FAK inhibitors based on cyclization strategy

Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors

Design and structure-based study of new potential FKBP12 inhibitors.

Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors

Pyrazolidine-3,5-dione Derivatives As Potent Non-Steroidal Agonists of Farnesoid X Receptor: Virtual Screening, Synthesis, and Biological Evaluation.

Discovery of Novel and Selective SIK2 Inhibitors by the Application of AlphaFold Structures and Generative Models.

Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction